Page last updated: 2024-10-17

lactic acid and Delirium of Mixed Origin

lactic acid has been researched along with Delirium of Mixed Origin in 9 studies

Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.

Research Excerpts

ExcerptRelevanceReference
"In 8 studies of 235 patients, delirium was associated with: elevated serotonin metabolites, interleukin-8, cortisol, lactate and protein, and reduced somatostatin, β-endorphin and neuron-specific enolase."4.87A systematic literature review of cerebrospinal fluid biomarkers in delirium. ( Hall, RJ; Maclullich, AM; Shenkin, SD, 2011)
"The new definitions of sepsis and septic shock reflect the inadequate sensitivity, specify, and lack of prognostication of systemic inflammatory response syndrome criteria."2.55Sepsis and Septic Shock Strategies. ( Armstrong, BA; Betzold, RD; May, AK, 2017)
"Postoperative delirium is associated with a breakdown in the BBB."1.72Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study. ( Blennow, K; Casey, CP; Kunkel, D; Lennertz, RC; Parker, M; Pearce, RA; Rivera, C; Sanders, RD; Tanabe, S; Taylor, J; Zetterberg, H, 2022)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's0 (0.00)29.6817
2010's7 (77.78)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Taylor, J1
Parker, M1
Casey, CP1
Tanabe, S1
Kunkel, D1
Rivera, C1
Zetterberg, H1
Blennow, K1
Pearce, RA1
Lennertz, RC1
Sanders, RD1
Armstrong, BA1
Betzold, RD1
May, AK1
Kroll, MW1
Hail, SL1
Kroll, RM1
Wetli, CV1
Criscione, JC1
Jauchem, JR3
Rothberger, GD1
Desai, AK1
Sharif, S1
Chawla, SA1
Shirazian, S1
Hall, RJ1
Shenkin, SD1
Maclullich, AM1
Abe, K1
Fujimura, H1
Nishikawa, Y1
Yorifuji, S1
Mezaki, T1
Hirono, N1
Nishitani, N1
Kameyama, M1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Detection and Neurological Impact of CerebroVascular Events In Noncardiac Surgery PatIents: A COhort EvaluatioN[NCT01980511]1,116 participants (Actual)Observational2014-03-24Completed
Interventions for Postoperative Delirium: Biomarker-3[NCT03124303]310 participants (Anticipated)Observational2017-02-13Recruiting
Interventions for Postoperative Delirium: Biomarker-2 (IPOD-B2) Pilot Study[NCT02926417]32 participants (Actual)Observational2016-06-30Completed
Mortality Due to Septic Shock Associated With Thrombocytopenia in the Intensive Care Unit[NCT03617965]350 participants (Anticipated)Observational2018-08-15Active, not recruiting
Phase 3 Trial of Coenzyme Q10 in Mitochondrial Disease[NCT00432744]Phase 324 participants (Actual)Interventional2007-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

McMaster Gross Motor Function (GMFM 88)

The McMaster Gross Motor Function is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. One of the links in this report is to the the GMFM scale and how it is scored. A link to the instrument is included. (NCT00432744)
Timeframe: Taken at 6 and 12 Months

Interventionunits on a scale (Median)
Placebo First-0.002
CoenzymeQ10 Frist-0.12

Non-parametric Hotelling T-square Bivariate Analysis of GMGF 88 and OPeds QOL.

This is a multivariate analysis of the first two outcomes: Period 2 minus Period 1 GMFM88 and Peds Quality of Life, analyzed as follows: First, to be in the analysis, subjects must contribute at least one of these endpoints. Second, if the subject became totally disabled during period 1, the difference was defined as + infinity, (highest possible evidence favoring period 2), and if the subject became totally disabled in period 2, the subject was scored as - infinity (highest possible evidence favoring period 1). Period 2 minus period 1 differences were ranked form low to high with missing values scores at the mid-rank. The Hotelling T-square was computed on these ranks and the P-value was obtained from 100,000 rerandomizations as the fraction of rerandomizations with T-sq at least as large as that observed. (NCT00432744)
Timeframe: end of 12 month minus end of 6 month difference.

Interventionparticipants (Number)
Placebo First7
CoenzymeQ10 Frist8

Pediatric Quality of Life Scale

"The Pediatric Quality of Life Scale is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. Goggle pedsQL and Mapi to browse the copyrighted manual. A link to the instrument is included." (NCT00432744)
Timeframe: At 6 and 12 Months

Interventionunits on a scale (Median)
Placebo First-1.1
CoenzymeQ10 Frist-11.9

Reviews

5 reviews available for lactic acid and Delirium of Mixed Origin

ArticleYear
Sepsis and Septic Shock Strategies.
    The Surgical clinics of North America, 2017, Volume: 97, Issue:6

    Topics: Anti-Bacterial Agents; Arterial Pressure; Cardiomyopathies; Central Venous Pressure; Critical Care;

2017
Exposures to conducted electrical weapons (including TASER® devices): how many and for how long are acceptable?
    Journal of forensic sciences, 2015, Volume: 60 Suppl 1

    Topics: Animals; Blood Glucose; Conducted Energy Weapon Injuries; Creatine Kinase; Delirium; Electric Stimul

2015
Deaths in custody: are some due to electronic control devices (including TASER devices) or excited delirium?
    Journal of forensic and legal medicine, 2010, Volume: 17, Issue:1

    Topics: Acidosis; Animals; Cause of Death; Confounding Factors, Epidemiologic; Delirium; Electroshock; Fever

2010
Pathophysiologic changes due to TASER® devices versus excited delirium: potential relevance to deaths-in-custody?
    Journal of forensic and legal medicine, 2011, Volume: 18, Issue:4

    Topics: Acidosis; Animals; Blood Glucose; Body Temperature; Catecholamines; Channelopathies; Conducted Energ

2011
A systematic literature review of cerebrospinal fluid biomarkers in delirium.
    Dementia and geriatric cognitive disorders, 2011, Volume: 32, Issue:2

    Topics: Acetylcholinesterase; beta-Endorphin; Biomarkers; Brain; Delirium; Dopamine; Humans; Hydrocortisone;

2011

Other Studies

4 other studies available for lactic acid and Delirium of Mixed Origin

ArticleYear
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
    British journal of anaesthesia, 2022, Volume: 129, Issue:2

    Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis

2022
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
    British journal of anaesthesia, 2022, Volume: 129, Issue:2

    Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis

2022
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
    British journal of anaesthesia, 2022, Volume: 129, Issue:2

    Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis

2022
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
    British journal of anaesthesia, 2022, Volume: 129, Issue:2

    Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis

2022
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
    British journal of anaesthesia, 2022, Volume: 129, Issue:2

    Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis

2022
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
    British journal of anaesthesia, 2022, Volume: 129, Issue:2

    Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis

2022
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
    British journal of anaesthesia, 2022, Volume: 129, Issue:2

    Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis

2022
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
    British journal of anaesthesia, 2022, Volume: 129, Issue:2

    Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis

2022
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
    British journal of anaesthesia, 2022, Volume: 129, Issue:2

    Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis

2022
Electrical weapons and excited delirium: shocks, stress, and serum serotonin.
    Forensic science, medicine, and pathology, 2018, Volume: 14, Issue:4

    Topics: Adult; Delirium; Electric Stimulation; Female; Healthy Volunteers; Humans; Hydrocortisone; Lactic Ac

2018
The Case | Elevated lactate and osmolar gap after levothyroxine overdose.
    Kidney international, 2015, Volume: 88, Issue:2

    Topics: Acidosis; Adult; Calcium Oxalate; Delirium; Drug Overdose; Ethylene Glycol; Female; Humans; Lactic A

2015
Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS).
    Acta neurologica Scandinavica, 1991, Volume: 83, Issue:6

    Topics: Acidosis, Lactic; Adult; Agnosia; Cerebrovascular Disorders; Delirium; Dose-Response Relationship, D

1991